Advertisement

Emergency Radiology

, Volume 11, Issue 2, pp 83–86 | Cite as

Acute treatment for ischemic stroke in 2004

  • Yousef M. Mohammad
  • Afshin A. Divani
  • Jawad F. Kirmani
  • Pansy Harris-Lane
  • Adnan I. Qureshi
Review Article

Abstract

The last decade witnessed significant and unprecedented advances in the treatment of acute ischemic stroke. Intravenous tissue plasminogen activator and defibrinogenating agent are both now approved by the Food and Drug Administration for treatment of acute ischemic stroke within 3 h of symptom onset. Trials involving intra-arterial thrombolysis have demonstrated clinical benefit in patients treated within 6 h of symptom onset. The future for the development of new and better treatment for ischemic stroke looks very promising. Currently, induced hypothermia, laser evaporation, mechanical thrombectomy, angioplasty with stent placement, the combination of neuroprotective agents with thrombolysis, and the combination of intravenous with intra-arterial thrombolysis are being investigated.

Keywords

Acute treatment Ischemic stroke Intra-venous thrombolysis Intra-arterial thrombolysis Thrombectomy devices Neuroprotective agents Hypothermia 

References

  1. 1.
    American Heart Association (2003) Heart Disease and Stroke Statistics—2004 update. American Heart Association, Dallas, TxGoogle Scholar
  2. 2.
    Anonymous (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349:1569–1581CrossRefPubMedGoogle Scholar
  3. 3.
    Anonymous (1998) Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 279:1265–1272PubMedGoogle Scholar
  4. 4.
    Hankey GJ, Sudlow CL, Dunbabin DW (2000) Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients (Cochrane review). Wiley, Chichester (Cochrane Library, issue 2)Google Scholar
  5. 5.
    Sandercock P, Gubitz G, Foley P, Counsell C (2004) Antiplatelet therapy for acute ischaemic stroke (Cochrane review). Wiley, Chichester (Cochrane Library, issue 2)Google Scholar
  6. 6.
    Anonymous (1994) Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators. Stroke 25:1755–1759Google Scholar
  7. 7.
    Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE (2000) Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 283:2395–2403CrossRefPubMedGoogle Scholar
  8. 8.
    Liu M, Counsell C, Zhao XL, Wardlaw J (2003) Fibrinogen depleting agents for acute ischaemic stroke (Cochrane review). Wiley, Chichester (Cochrane Library, issue 2)Google Scholar
  9. 9.
    Anonymous (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333:1581–1587CrossRefPubMedGoogle Scholar
  10. 10.
    Osborn TM, LaMonte MP, Gaasch WR (1999) Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies. Ann Emerg Med 34:244–55PubMedGoogle Scholar
  11. 11.
    Anonymous (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768–774CrossRefPubMedGoogle Scholar
  12. 12.
    del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29:4–11PubMedGoogle Scholar
  13. 13.
    Qureshi AI (2002) New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. Neurosurgery 50:1405–1414PubMedGoogle Scholar
  14. 14.
    Qureshi AI (2004) Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 363:804–813CrossRefPubMedGoogle Scholar
  15. 15.
    Boulos AS, Levy EI, Bendok BR, Kim SH, Qureshi AI, Guterman LR, Hopkins LN (2004) Evolution of neuroendovacular intervention: a review of advancement in device technology. Neurosurgery 54:438–453PubMedGoogle Scholar
  16. 16.
    Janardhan V, Qureshi AI (2004) Mechanisms of ischemic brain injury. Curr Cardiol Rep 6:117–123PubMedGoogle Scholar
  17. 17.
    Nolan JP, Morley PT, Vanden Hoek TL, Hickey RW, Kloeck WG, Billi J, Bottiger BW, Morley PT, Nolan JP, Okada K, Reyes C, Shuster M, Steen PA, Weil MH, Wenzel V, Hickey RW, Carli P, Vanden Hoek TL, Atkins D (2003) International Liaison Committee on Resuscitation. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 108:118–121CrossRefPubMedGoogle Scholar
  18. 18.
    Krieger DW, De Georgia MA, Abou-Chebl A, Andrefsky JC, Sila CA, Katzan IL, Mayberg MR, Furlan AJ (2001) Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke. Stroke 32:1847–1854PubMedGoogle Scholar

Copyright information

© Am Soc Emergency Radiol 2004

Authors and Affiliations

  • Yousef M. Mohammad
    • 1
  • Afshin A. Divani
    • 2
  • Jawad F. Kirmani
    • 2
  • Pansy Harris-Lane
    • 2
  • Adnan I. Qureshi
    • 2
  1. 1.Department of NeurologyOhio State UniversityColumbusUSA
  2. 2.Cerebrovascular ProgramDepartment of Neurology and Neurosciences, New Jersey Medical SchoolNewarkUSA

Personalised recommendations